tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Elicio Therapeutics Advances Phase 2 AMPLIFY-7P Study

Story Highlights
  • Elicio Therapeutics received a recommendation to continue its Phase 2 study for ELI-002 7P.
  • The study showed preliminary efficacy signals, with a final analysis expected in Q4 2025.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Elicio Therapeutics Advances Phase 2 AMPLIFY-7P Study

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Elicio Therapeutics ( (ELTX) ).

On August 5, 2025, Elicio Therapeutics announced that an Independent Data Monitoring Committee recommended the continuation of its Phase 2 AMPLIFY-7P study without modifications, following a positive interim review of safety and efficacy data for ELI-002 7P in treating mutant KRAS-driven pancreatic ductal adenocarcinoma. This recommendation indicates preliminary efficacy signals, and Elicio plans to proceed with a final disease-free survival analysis in Q4 2025. The company has aligned with the FDA on the Phase 3 study design and plans to expand ELI-002 to other indications.

The most recent analyst rating on (ELTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Elicio Therapeutics stock, see the ELTX Stock Forecast page.

Spark’s Take on ELTX Stock

According to Spark, TipRanks’ AI Analyst, ELTX is a Underperform.

Elicio Therapeutics faces significant financial challenges, with negative revenue growth and poor margins being the primary concerns. Technical analysis indicates bearish momentum, while the valuation aspect shows limited appeal. However, recent positive corporate events, such as leadership changes and clinical advancements, provide some optimism for future potential, albeit with high risk.

To see Spark’s full report on ELTX stock, click here.

More about Elicio Therapeutics

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers such as mutant KRAS-positive pancreatic and colorectal cancers. The company aims to advance effective off-the-shelf vaccines using its proprietary Amphiphile (AMP) technology, which enhances the activation of cancer-specific T cells.

Average Trading Volume: 43,501

Technical Sentiment Signal: Buy

Current Market Cap: $159.6M

See more insights into ELTX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1